Canaccord raised the firm’s price target on Insulet (PODD) to $450 from $432 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year. Canaccord believs Insulet is positioned for a multi-year cycle of outperformance supported by the recent label expansion and commercialization of AID systems into the T2D patient population.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet initiated with an Outperform at Evercore ISI
- NVDA, LLY, AMD, PODD, DIS: Top 5 Strong Buy “Growth Stocks” for 2026
- 3 “Strong Buy” Growth Stocks to Buy Now, According to Analysts – 12/8/2025
- Insulet gets FDA clearance for updates to Omnipod 5 Automated Insulin Delivery
- Insulet price target raised to $432 from $428 at Canaccord